Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors A total of 14,177 patients were ...

Samsung Medical Center announced that its researchers have developed a new AI model capable of predicting the recurrence risk of non-small cell lung cancer up to a year in advance. According to the ...

Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...

Despite recommendations for posttreatment surveillance in lung cancer patients, there is wide variability in the follow-up care that lung cancer patients receive. A recent study, led by senior ...

AWARENESS MONTH. IF YOU DIDN’T KNOW A TIME TO HIGHLIGHT PREVENTION, TREATMENT AND OF COURSE, SURVIVORS HERE TO DISCUSS THE CURRENT RISE IN LUNG CANCER IN NONSMOKERS AND HOW TO COMBAT IT, IS DOCTOR ...

Black Diamond posts strong Phase 2 lung cancer results with a 60% response rate and solid safety profile while preparing ...

Bundang Seoul National University Hospital (Director Song Jeong-han) achieved a cumulative 10,000 cases of lung cancer ...